Precigen, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsPrecigen is a commercial-stage biopharmaceutical company whose near-term fate hinges on the U.S. launch of Papzimeos, its first FDA-approved therapy for recurrent respiratory papillomatosis.
What they do
Precigen develops precision medicines using its AdenoVerse immunotherapy and UltraCAR-T platforms. Its only approved product, Papzimeos, treats adults with recurrent respiratory papillomatosis (RRP), a rare HPV-driven disease. The pipeline includes PRGN-2009 (AdenoVerse) and UltraCAR-T candidates PRGN-3005, PRGN-3006, and PRGN-3007, with enrollment paused in two of those trials.
Revenue drivers
- Papzimeos (US commercial sales) — Only source of revenue; Q2 2026 net revenue was $53.1M, more than double Q1 2026's $23.3M total company revenue.
- Papzimeos patient hub and access — Over 500 patients enrolled in the hub, with payer coverage across ~315M US lives and a permanent J-code (J3404) effective April 1, 2026.
Recent performance
In Q2 2026, total revenue was $55.0M, up from $856k in Q2 2025, driven by Papzimeos. The company reported quarterly profitability for the first time. Cash, equivalents, and investments totaled $38.7M at June 30, 2026, with long-term debt of $93.9M. For full-year 2025, revenue was $9.7M with a net loss of $250.6M.
Strategy
Management is focused on expanding Papzimeos globally and into pediatric patients, leveraging the AdenoVerse platform to target HPV-associated diseases. They are advancing PRGN-2009 in HPV-driven cancers under a CRADA with the NCI, with a pipeline update expected by year-end 2026. Commercial strategy emphasizes 100% field engagement with target accounts, active patient/HCP campaigns, and a permanent J-code to support reimbursement and site activation. The company aims to achieve cash flow break-even by the end of 2026, using Papzimeos revenue to fund operations.
Risks
- Concentration on a single product — Near-term prospects depend substantially on the commercial success of Papzimeos, and any shortfall would materially hurt revenue and cash flow.
- Regulatory and geographic expansion delays — Approval outside the U.S. is not assured; the company is seeking European Commission approval and preparing filings elsewhere, with no guarantee of success.
- Cash burn and liquidity — Operating cash flow was negative $87.8M in 2025 and cash plus investments was only $38.7M at June 30, 2026, so continued losses or slower-than-expected Papzimeos sales could force additional financing.
- Pipeline uncertainty — UltraCAR-T and AdenoVerse candidates are early stage; PRGN-3005 and PRGN-3007 enrollment is paused, reflecting the company's own strategic prioritization.
Outlook
Management expects Papzimeos revenue growth to continue, supporting cash flow break-even by the end of 2026. They plan to provide a pipeline update on PRGN-2009 by year-end. Redosing study for Papzimeos is enrolling, and the company is preparing for global regulatory submissions.